NCT05860244View on ClinicalTrials.gov

Effect of Salbutamol on Walking Capacity in Ambulatory ALS Patients

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

September 30, 2024

Primary Completion Date

July 31, 2025

Study Completion Date

July 31, 2025

Conditions
Walking CapacityAmyotrophic Lateral Sclerosis
Interventions
DRUG

Salbutamol

Salbutamol for 6 months

DRUG

Placebo

Placebo Syrup for 6 months

Trial Locations (1)

75013

Hôpital Pitié Salpêtrière, Paris

All Listed Sponsors
lead

Assistance Publique - Hôpitaux de Paris

OTHER

NCT05860244 - Effect of Salbutamol on Walking Capacity in Ambulatory ALS Patients | Biotech Hunter | Biotech Hunter